* Dare Bioscience Inc is expected to show a rise in quarterly revenue when it reports results on November 14 for the period ending September 30 2024

* The San Diego California-based company is expected to report a 304.6% increase in revenue to $4.046 million from $1 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Dare Bioscience Inc is for a loss of 73 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the pharmaceuticals peer group is also "Buy".​

* Wall Street's median 12-month price target for Dare Bioscience Inc is 13.00​, above​ its last closing price of $4.41. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jan. 1 0001 -0.65 0.00 -0.88 Missed

Mar. 31 0001 -0.72 -0.72 -0.84 Missed -16.7

Dec. 31 2023 -1.60 -1.18 -0.72 Beat 38.8​

Sep. 30 2023 -1.16 -1.18 -1.08 Beat 8.2

​​Jun. -1.21 -1.18 -1.20 Missed -1.7

30 2023

Mar. 31 2023 -1.22 -1.20 -1.08 Beat 10​

Jan. 1 0001 -1.62 -1.64 -2.28 Missed -39

Sep. 30 2022 -1.35 -1.41 -0.96 Beat 31.9

This summary was machine generated November 13 at 00:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)